Cargando…
Role of STAT3 in Transformation and Drug Resistance in CML
Chronic myeloid leukemia (CML) is initially driven by the bcr–abl fusion oncoprotein. The identification of bcr–abl led to the discovery and rapid translation into the clinic of bcr–abl kinase inhibitors. Although, bcr–abl inhibitors are efficacious, experimental evidence indicates that targeting bc...
Autores principales: | Nair, Rajesh R., Tolentino, Joel H., Hazlehurst, Lori A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355894/ https://www.ncbi.nlm.nih.gov/pubmed/22649784 http://dx.doi.org/10.3389/fonc.2012.00030 |
Ejemplares similares
-
STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance
por: Poli, Valeria, et al.
Publicado: (2015) -
Metabolic alterations mediated by STAT3 promotes drug persistence in CML
por: Patel, Sweta B., et al.
Publicado: (2021) -
CD44 in Ovarian Cancer Progression and Therapy Resistance—A Critical Role for STAT3
por: Martincuks, Antons, et al.
Publicado: (2020) -
Resistant mutations in CML and Ph(+)ALL – role of ponatinib
por: Miller, Geoffrey D, et al.
Publicado: (2014) -
Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19
por: Luan, Chengxin, et al.
Publicado: (2022)